These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9651283)

  • 1. Hypertension treatment and control in Sub-saharan Africa. Figure of $1800 per life saved seems optimistic.
    Burdon J
    BMJ; 1998 Jul; 317(7150):76; author reply 77. PubMed ID: 9651283
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypertension treatment and control in Sub-saharan Africa. Burden of cerebrovascular disease will increase as more people survive to old age.
    Walker R; Unwin N; Alberti KG
    BMJ; 1998 Jul; 317(7150):76-7; author reply 77. PubMed ID: 9705634
    [No Abstract]   [Full Text] [Related]  

  • 3. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 6. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic issues and the future treatment and management of hypertension.
    Giles TD
    AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypertensive disease in subjects born in sub-Saharan Africa or in Europe referred to a hypertension unit: a cross-sectional study].
    Gombet T; Steichen O; Plouin PF
    Bull Acad Natl Med; 2007 Nov; 191(8):1745-54; discussion 1754-5. PubMed ID: 18666471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
    Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM
    Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
    Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
    Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
    Anlauf M; Hense HW
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
    [No Abstract]   [Full Text] [Related]  

  • 13. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost considerations in the drug treatment of hypertension. Is older better?
    Kaplan NM
    Pharmacoeconomics; 1996 Apr; 9(4):283-5. PubMed ID: 10160102
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 17. Why is control of hypertension in sub-Saharan Africa poor?
    Seedat YK
    Cardiovasc J Afr; 2015; 26(4):193-5. PubMed ID: 26407222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comment on IOWiG report plan. A medical decision may not be replaced].
    Vorstand der Deutschen Hochdruckliga E.V
    MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
    [No Abstract]   [Full Text] [Related]  

  • 19. NIH promotes use of lower cost drugs for hypertension.
    Spurgeon D
    BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypertension control: improved, but not enough!
    Alderman MH
    Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.